AGP Executive Report
Last update: 10 hours agoCancer Breakthroughs at ASCO: Doctors called a new triple-action injection “unprecedented” after it reportedly drove complete tumor disappearance in some advanced head-and-neck cancer patients, while multiple other late-stage updates highlighted major gains across hard-to-treat disease. Targeted Prostate Care: The phase 3 PROTEUS trial found perioperative apalutamide plus ADT cut the risk of metastasis or death and boosted pathologic complete response rates for high-risk localized prostate cancer. Pancreatic Cancer Hope: A daily pill, daraxonrasib, nearly doubled median survival for metastatic pancreatic cancer patients with KRAS mutations versus chemotherapy, and early reports also pointed to durable responses. Biotech Pipeline Signals: ASCO updates included Imugene’s off-the-shelf CAR-T showing responses across several blood cancer subtypes, plus Oricell’s GPC3 CAR-T posting strong response rates in late-line liver cancer. Illinois Tech & Policy: Illinois lawmakers advanced a statewide school cellphone ban, and Naperville picked the I-88 corridor for a 2026 special study. Agriculture & Tech: U. of I researchers used satellite imagery and machine learning to map long-term tillage trends across the Corn Belt, and a clean energy manufacturing report projected rapid growth in U.S. facilities by 2030.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
